Total Payments
$76,940
2024 Payments
$65,874
Companies
26
Transactions
149
Payment Breakdown by Category
Research$72,480 (94.2%)
Travel$2,403 (3.1%)
Food & Beverage$2,058 (2.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,480 | 48 | 94.2% |
| Travel and Lodging | $2,403 | 12 | 3.1% |
| Food and Beverage | $2,058 | 89 | 2.7% |
Payments by Type
Research
$72,480
48 transactions
General
$4,460
101 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $66,512 | 6 | $0 (2024) |
| Allergan Inc. | $4,202 | 25 | $0 (2018) |
| GlaxoSmithKline, LLC. | $1,872 | 20 | $0 (2020) |
| AstraZeneca UK Limited | $1,476 | 8 | $0 (2018) |
| AbbVie, Inc. | $1,054 | 13 | $0 (2019) |
| Amgen Inc. | $723.70 | 12 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $180.96 | 2 | $0 (2018) |
| Novo Nordisk Inc | $130.84 | 10 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $90.98 | 5 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $73.98 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,874 | 3 | Eli Lilly and Company ($65,874) |
| 2021 | $145.50 | 1 | Eli Lilly and Company ($145.50) |
| 2020 | $2,174 | 19 | GlaxoSmithKline, LLC. ($1,819) |
| 2019 | $1,053 | 13 | AbbVie, Inc. ($1,024) |
| 2018 | $3,364 | 52 | AstraZeneca UK Limited ($1,476) |
| 2017 | $4,329 | 61 | Allergan Inc. ($3,125) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $22,999.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | ||||||
| 11/25/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $40,272.00 | Research |
| Study: A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | ||||||
| 10/28/2024 | Eli Lilly and Company | — | — | In-kind items and services | $2,603.10 | Research |
| Study: A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | ||||||
| 01/29/2021 | Eli Lilly and Company | — | — | In-kind items and services | $145.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 10/30/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Diabetes | ||||||
| 08/24/2020 | Eli Lilly and Company | — | — | In-kind items and services | $342.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 02/05/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $42.00 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 02/05/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $28.75 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $400.59 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $377.06 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $202.68 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $160.53 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $107.14 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $93.64 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $85.27 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $72.66 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $61.76 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $36.54 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $34.85 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $32.79 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $30.74 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $27.44 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $24.23 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 10/22/2019 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Obesity | ||||||
| 05/20/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $54.00 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | Eli Lilly and Company | $42,875 | 2 |
| A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $22,999 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $2,139 | 9 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,819 | 17 |
| M16-100 | AbbVie, Inc. | $1,024 | 11 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $986.00 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $488.00 | 2 |
| AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | Eli Lilly and Company | $150.00 | 1 |
About Dr. Donna Desantis, MD
Dr. Donna Desantis, MD is a Family Medicine healthcare provider based in Mesa, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962483727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donna Desantis, MD has received a total of $76,940 in payments from pharmaceutical and medical device companies, with $65,874 received in 2024. These payments were reported across 149 transactions from 26 companies. The most common payment nature is "" ($72,480).
Ad
Practice Information
- Specialty Family Medicine
- Location Mesa, AZ
- Active Since 11/09/2005
- Last Updated 10/27/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1962483727
Products in Payments
- NUCALA (Biological) $1,819
- Androgel (Drug) $1,042
- Repatha (Biological) $632.46
- FARXIGA (Drug) $102.97
- JARDIANCE (Drug) $69.82
- Vascepa (Drug) $60.00
- Prolia (Biological) $53.68
- Baxdela (Drug) $49.68
- XARELTO (Drug) $48.54
- SOLIQUA (Drug) $47.73
- MYDAYIS (Drug) $46.98
- Victoza (Drug) $46.55
- XIFAXAN (Drug) $35.85
- JANUVIA (Drug) $32.89
- ClosureFast (Device) $32.65
- Saxenda (Drug) $29.30
- Ozempic (Drug) $28.16
- TOUJEO (Drug) $26.25
- VYVANSE (Drug) $24.68
- CONTRAVE (Drug) $23.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Mesa
Terry O'reilly, M.d, M.D
Family Medicine — Payments: $586,349
Family Medicine $586,349
Suzanne Bentz, Do, DO
Family Medicine — Payments: $165,113
Family Medicine $165,113
Cory Anderson, Md, MD
Family Medicine — Payments: $152,799
Family Medicine $152,799
Yadwinder Dhillon, M.d, M.D
Family Medicine — Payments: $51,311
Family Medicine $51,311
Dr. Karen Acevedo-Mogharbel, D.o, D.O
Family Medicine — Payments: $46,281
Family Medicine $46,281
James Gunn, M.d, M.D
Family Medicine — Payments: $17,717
Family Medicine $17,717